Cancer Treatment News and Research

RSS

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

The World Health Organization (WHO) today published the new edition of its Model List of Essential Medicines) which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others...

8 May 2015

CCM and MD Anderson partner to improve cancer care in China, Singapore

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, announced today that it has signed a multi-year strategic development agreement with The University of Texas MD Anderson Cancer Center, an internationally renowned cancer research, treatment and education center.

6 May 2015

First patient receives new 'resistance-busting' experimental skin cancer drug

A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.

6 May 2015

Frederick Alt honored with 2015 Szent-Györgyi Prize for Progress in Cancer Research

Frederick Alt, PhD, director of the Program in Cellular and Molecular Medicine at Boston Children's Hospital, has been honored with the 2015 Szent-Györgyi Prize for Progress in Cancer Research.

4 May 2015

New discovery may change the principles for treating cancer

Danish researchers from the University of Copenhagen and Herlev Hospital have made a discovery that may change the principles for treating certain types of cancer.

30 Apr 2015

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer.

29 Apr 2015

PCDx test performs better than FoundationOne test in clinical study

Data from a small cohort published OncoTargets and Therapy today shows that the Paradigm Cancer Diagnostic Test (PCDx) performed better than Foundation Medicine's FoundationOne test across a number of key clinical variables, including turnaround time (TAT) and clinically actionable biomarker targets.

28 Apr 2015

Research findings could offer new way to test for chemo brain in patients

UBC research shows that chemotherapy can lead to excessive mind wandering and an inability to concentrate. Dubbed 'chemo-brain,' the negative cognitive effects of the cancer treatment have long been suspected, but the UBC study is the first to explain why patients have difficulty paying attention.

28 Apr 2015

Molecular Health granted European patent for novel Erythropoietin receptor

Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.

27 Apr 2015

Xstrahl introduces Phtotoelectric therapy to the European market at ESTRO 2015

Utilising trusted and clinically proven low energy photons, in a dedicated treatment system. Photoelectric Therapy provides a pain free, non-surgical alternative for the treatment of non-melanoma skin cancer, especially those found in sensitive areas of the head and neck...

24 Apr 2015

ADCs based on alpha-amanatin may help treat colorectal cancer

For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited.

23 Apr 2015

Purdue University study sheds light on how decitabine drug reverses cell damage

A Purdue University study sheds light on how cell damage is reversed by the cancer drug decitabine and identifies a potential biomarker that could indicate a patient's stage of cancer and response to treatment.

23 Apr 2015

Advances in thoracic surgery: an interview with Dan Wildman, VP Global Franchise Strategy & Innovation- Ethicon

Without a doubt, one of the most significant developments in thoracic surgery was the advent of video-assisted thoracoscopic surgery or VATS in the 1990s...

22 Apr 2015

Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

Scientists at Tel Aviv Medical Center, Israel, have found that oral modified citrus pectin (MCP) enhances the anti-cancer and anti-metastatic effects of radiation therapy in the treatment of androgen-independent (AI) aggressive prostate cancer cells.

22 Apr 2015

Botanical formula improves effect of tamoxifen drug in ER+ human breast cancer

Researchers at the Cancer Research Laboratory, Methodist Research Institute, Indiana University Health found that a botanical formula for breast health inhibited the growth of estrogen receptor-positive (ER+) human breast cancer cells. More importantly, the researchers also found that the formula enhanced the anti-cancer benefits of the drug tamoxifen in the treatment of breast cancer.

22 Apr 2015

Unique approach to academia-industry training could help improve proton therapy treatment

Improving proton therapy for cancer treatment is one of the many advances in accelerator science that have been fast-tracked by a unique approach to academia-industry training, led by the Cockcroft Institute. The two programmes, which have produced 42 highly valued research fellows, are drawing to a conclusion and industry partners are warning of a skills chasm in the very near future unless further training is prioritised.

22 Apr 2015

New Dream Team dedicated to ovarian cancer research formed at AACR Annual Meeting 2015

Stand Up To Cancer, Ovarian Cancer Research Fund, Ovarian Cancer National Alliance, and National Ovarian Cancer Coalition, along with the American Association for Cancer Research, Scientific Partner to SU2C, announced today the formation of a Dream Team devoted to ovarian cancer research at the AACR Annual Meeting 2015, held here April 18-22.

21 Apr 2015

Designing AR Inhibitors Team wins AACR Team Science Award for developing prostate cancer treatment

The American Association for Cancer Research will award the ninth annual AACR Team Science Award to the Designing Androgen Receptor (AR) Inhibitors Team from Memorial Sloan Kettering Cancer Center and the University of California, Los Angeles at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

21 Apr 2015

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

The University of New Mexico Cancer Center recently enrolled its first patient in a phase 3 international clinical trial to test a personalized vaccine against metastatic kidney cancer. Kidney cancer has proven particularly difficult to treat with chemotherapy, and numerous attempts to create a kidney cancer vaccine have not improved survival rates.

20 Apr 2015

CAP pathologist shares four tips for women with breast cancer

For any woman, a diagnosis of breast cancer can be frightening. But as Rita Wilson's recent experience shows, engaging with the keystone of the diagnosis - the pathology report - can be critical in achieving good outcomes. Informed by rigorous scientific processes, training and team discussion, pathology reports identify a diagnosis, help indicate the right providers for a patient's care team and shape treatment plans.

20 Apr 2015

Cancer Treatment News and Research

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

CCM and MD Anderson partner to improve cancer care in China, Singapore

First patient receives new 'resistance-busting' experimental skin cancer drug

Frederick Alt honored with 2015 Szent-Györgyi Prize for Progress in Cancer Research

New discovery may change the principles for treating cancer

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

PCDx test performs better than FoundationOne test in clinical study

Research findings could offer new way to test for chemo brain in patients

Molecular Health granted European patent for novel Erythropoietin receptor

Xstrahl introduces Phtotoelectric therapy to the European market at ESTRO 2015

ADCs based on alpha-amanatin may help treat colorectal cancer

Purdue University study sheds light on how decitabine drug reverses cell damage

Advances in thoracic surgery: an interview with Dan Wildman, VP Global Franchise Strategy & Innovation- Ethicon

Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

Botanical formula improves effect of tamoxifen drug in ER+ human breast cancer

Unique approach to academia-industry training could help improve proton therapy treatment

New Dream Team dedicated to ovarian cancer research formed at AACR Annual Meeting 2015

Designing AR Inhibitors Team wins AACR Team Science Award for developing prostate cancer treatment

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

CAP pathologist shares four tips for women with breast cancer

Your guide to microplate readers for cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News